<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Neuropsychopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Neuropsychopharmacol</journal-id><journal-id journal-id-type="publisher-id">ijnp</journal-id><journal-title-group><journal-title>International Journal of Neuropsychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1461-1457</issn><issn pub-type="epub">1469-5111</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29016822</article-id><article-id pub-id-type="pmc">5737519</article-id><article-id pub-id-type="doi">10.1093/ijnp/pyx060</article-id><article-id pub-id-type="publisher-id">pyx060</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Research Articles</subject></subj-group><subj-group subj-group-type="category-oup-series"><subject>Editor's Choice</subject></subj-group></article-categories><title-group><article-title>Platelet-Derived Growth Factor as an Antidepressant Treatment Selection
Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI
Combination</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2764-2391</contrib-id><name><surname>Jha</surname><given-names>Manish K</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Minhajuddin</surname><given-names>Abu</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Gadad</surname><given-names>Bharathi S</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Trivedi</surname><given-names>Madhukar H</given-names></name><xref ref-type="aff" rid="AF0001">1</xref><xref ref-type="corresp" rid="c1"/><!--<email>madhukar.trivedi@utsouthwestern.edu</email>--></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Center for Depression Research and Clinical Care</institution> (Drs Jha, Gadad
and Trivedi), and <institution>Department of Clinical Sciences</institution> (Dr
Minhajuddin), <institution>University of Texas Southwestern Medical Center</institution>,
<addr-line>Dallas, Texas</addr-line>.</aff><author-notes><corresp id="c1">Correspondence: Madhukar H. Trivedi, MD, Professor of Psychiatry, Betty Jo
Hay Distinguished Chair in Mental Health, Director, Center for Depression Research and
Clinical Care, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd.,
Dallas, TX 75390&#x02013;9119 (<email>madhukar.trivedi@utsouthwestern.edu</email>).</corresp></author-notes><pub-date pub-type="collection"><month>11</month><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-07-23"><day>23</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>7</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>20</volume><issue>11</issue><fpage>919</fpage><lpage>927</lpage><history><date date-type="received"><day>26</day><month>5</month><year>2017</year></date><date date-type="rev-recd"><day>05</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>18</day><month>7</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of
CINP.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc" xlink:href="http://creativecommons.org/licenses/by-nc/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the
original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="pyx060.pdf"/><abstract><title>Abstract</title><sec id="s100"><title>Background</title><p>Platelet derived growth factor is integral to maintenance of blood brain barrier,
increases in response to blood brain barrier disruption, and may reflect
neuroinflammation. Based on previous reports of better outcomes with dopaminergic
antidepressants in depressed patients with elevated inflammatory biomarkers, we
hypothesize that elevated peripheral platelet derived growth factor levels can serve as
a powerful biomarker for selecting dopaminergic antidepressants.</p></sec><sec id="s101"><title>Methods</title><p>Platelet derived growth factor, basic fibroblast growth factor, and granulocyte colony
stimulating factor were measured as part of Bioplex Pro human cytokine 27-plex kit in
participants of the Combining Medications to Enhance Depression Outcomes trial who
provided baseline plasma (n=166) and were treated with either
bupropion-plus-escitalopram, escitalopram-plus-placebo, or venlafaxine-plus-mirtazapine.
Differential changes in overall symptom severity and anhedonia as well as side effects
were tested with a treatment-arm-by-biomarker interaction in mixed model analyses.
Effect of biomarkers with significant interaction was calculated in subsequent analyses
stratified by treatment arm.</p></sec><sec id="s102"><title>Results</title><p>There was a significant treatment-arm-by-platelet derived growth factor interaction for
depression severity (<italic>P</italic>=.03) and anhedonia (<italic>P</italic>=.008) but
not for side effects (<italic>P</italic>=.44). Higher baseline platelet derived growth
factor level was associated with greater reduction in depression severity (effect
size=0.71, <italic>P</italic>=.015) and anhedonia (effect size=0.66,
<italic>P</italic>=.02) in the bupropion- selective serotonin reuptake inhibitor but not
the other two treatment arms. There was no significant treatment-arm-by-biomarker
interaction for both depression severity and side effects with the other two
biomarkers.</p></sec><sec id="s103"><title>Conclusion</title><p>As compared with selective serotonin reuptake inhibitor monotherapy or
venlafaxine-plus-mirtazapine, bupropion-plus-escitalopram selectively improves
anhedonia, which in turn results in improved overall depression severity in depressed
patients with elevated platelet derived growth factor levels.</p></sec></abstract><kwd-group><kwd>inflammation</kwd><kwd>antidepressant</kwd><kwd>moderator</kwd><kwd>dopamine</kwd><kwd>PDGF</kwd></kwd-group><counts><page-count count="9"/></counts></article-meta></front><body><boxed-text position="float" orientation="portrait"><sec id="s104"><title>Significance Statement</title><p>Blood tests of inflammation can improve current &#x0201c;trial and error&#x0201d; based practice of
antidepressant selection by personalizing the choice between dopaminergic antidepressants
(e.g., bupropion) vs selective serotonin reuptake inhibitor antidepressants (SSRIs).
However, the mechanism underlying this differential effect is unclear. We found that
higher baseline levels of platelet-derived growth factor (PDGF), a potential marker of
inflammation in brain, is associated with greater overall symptomatic (effect size= 0.70)
and anhedonia (effect size= 0.66) improvement in depressed patients treated with
bupropion-SSRI combination. A similar effect was not seen with SSRI alone or a combination
of venlafaxine and mirtazapine. Improvement in anhedonia predominantly accounts for the
baseline PDGF-based improvement with bupropion-SSRI combination.</p></sec></boxed-text><sec id="s1"><title>Introduction</title><p>Elevated levels of pretreatment biomarkers of peripheral inflammation such as C-reactive
protein and interleukin 17 (IL-17) can guide selection of dopaminergic antidepressants over
predominantly serotonergic antidepressants (<xref rid="CIT0050" ref-type="bibr">Uher et al.,
2014</xref>; <xref rid="CIT0023a" ref-type="bibr">Jha et al. 2017a</xref>; <xref rid="CIT0029" ref-type="bibr">Miller et al., 2017a</xref>). Similarly, anti-cytokine
therapies have been shown to reduce symptom severity in depressed patients with elevated
peripheral inflammation (<xref rid="CIT0031" ref-type="bibr">Raison et al., 2013</xref>;
<xref rid="CIT0024" ref-type="bibr">Kappelmann et al., 2016</xref>). However, biological
mechanisms underlying neuroinflammation in depressed patients secondary to peripheral
inflammation remain unclear. In fact, it has been postulated that peripheral inflammation
may not always result in either neuroinflammation or major depression. In unselected groups
of depressed patients, levels of inflammatory biomarkers either do not correlate or
correlate modestly with depression severity (<xref rid="CIT0008" ref-type="bibr">Cassidy-Bushrow et al., 2012</xref>; <xref rid="CIT0007" ref-type="bibr">Bryleva et al.,
2017</xref>; <xref rid="CIT0023" ref-type="bibr">Jha et al., 2017b</xref>; <xref rid="CIT0027" ref-type="bibr">K&#x000f6;hler-Forsberg et al., 2017</xref>). Thus, identifying
peripheral markers in blood that reflect neuroinflammation may help with developing novel
treatments and could also identify specific subgroups that would require different
treatments, thus personalizing the choice of currently available antidepressants.</p><p>Among peripheral markers of inflammation, elevated levels of interleukin 6 in depressed
patients compared with controls (<xref rid="CIT0012" ref-type="bibr">Dowlati et al.,
2010</xref>; <xref rid="CIT0019" ref-type="bibr">Haapakoski et al., 2015</xref>), even
after controlling for obesity (<xref rid="CIT0040" ref-type="bibr">Shelton et al.,
2015</xref>), has been one of the most consistent findings. Elevated IL-6 promotes
production of IL-17 (<xref rid="CIT0011" ref-type="bibr">Dong, 2008</xref>). As shown in
panel <italic>A</italic> of <xref ref-type="fig" rid="F1">Figure 1</xref>, IL-17 binds to
the endothelial cells of blood brain barrier (BBB) and induces formation of reactive oxygen
species (<xref rid="CIT0022" ref-type="bibr">Huppert et al., 2010</xref>), which in turn
increases the permeability of BBB and facilitates the infiltration of peripheral immune
cells into the CNS (<xref rid="CIT0026" ref-type="bibr">Kebir et al., 2007</xref>). Elevated
stress and peripheral inflammation has also been shown to damage the BBB and facilitate
infiltration of monocytes in the CNS (<xref rid="CIT0056" ref-type="bibr">Wohleb et al.,
2014</xref>). In response to BBB damage, pericytes increase the synthesis of platelet
derived growth factor (PDGF) (<xref rid="CIT0002" ref-type="bibr">Arimura et al.,
2012</xref>). Hence, elevated levels of PDGF in periphery may reflect neuroinflammation as
supported by findings that higher levels of PDGF are inversely associated with integrity of
myelin sheaths in depressed patients (<xref rid="CIT0005" ref-type="bibr">Benedetti et al.,
2016</xref>).</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Platelet derived growth factor (PDGF) is a peripheral marker of neuroinflammation,
which predicts improved outcomes with bupropion. Elevated interleukin 6 (IL-6) in
depressed patients results in increased interleukin 17 (IL-17) levels (A), which binds
to the IL-17 receptors on endothelial cells of blood brain barrier (BBB). This results
in generation of reactive oxygen species (ROS), which along with stress can lead to BBB
damage and infiltration of peripheral immune cells in the CNS. Damage to the BBB has
been shown to increase PDGF. Neuroinflammation (B), as reflected by increased PDGF,
results in anhedonia, partially through diversion of tetrahydrobiopterin from dopamine
synthesis by activation of nitric oxide synthase (NOS) in microglia. Bupropion is a
dopaminergic antidepressant that ameliorates anhedonia and may be preferentially
effective in depressed patients with elevated PDGF levels.</p></caption><graphic xlink:href="pyx06001"/></fig><p>As shown in panel <italic>B</italic> of <xref ref-type="fig" rid="F1">Figure 1</xref>, BBB
damage results in infiltration of peripheral immune cells as well as IL-17 within the CNS.
Microglial cells express IL-17 receptors (<xref rid="CIT0025" ref-type="bibr">Kawanokuchi et
al., 2008</xref>); binding of IL-17 to microglial receptors induces nitric oxide synthase
(NOS) and inflammatory cytokines (<xref rid="CIT0025" ref-type="bibr">Kawanokuchi et al.,
2008</xref>; <xref rid="CIT0038" ref-type="bibr">Sarma et al., 2009</xref>), which in turn
leads to reduced synthesis of dopamine by diversion of tetrahydrobiopterin, an essential
cofactor of NOS and tyrosine hydroxylase, away from rate limiting step (conversion of
tyrosine to L-3,4-dihydroxyphenylalanine) in dopamine synthesis (<xref rid="CIT0030" ref-type="bibr">Miller et al., 2017b</xref>). This results in the changes in brain dopamine
metabolism (<xref rid="CIT0016" ref-type="bibr">Felger, 2017</xref>) as well as the
reductions in effort-based motivation for reward in animals (<xref rid="CIT0051" ref-type="bibr">Vichaya et al., 2014</xref>). In human beings, inflammation is associated
with anhedonia (<xref rid="CIT0013" ref-type="bibr">Eisenberger et al., 2010</xref>; <xref rid="CIT0017" ref-type="bibr">Felger et al., 2016</xref>; <xref rid="CIT0042" ref-type="bibr">Swardfager et al., 2016</xref>), and peripheral inflammation has been shown
to reduce the connectivity of corticostriatal reward circuitry in depressed patients (<xref rid="CIT0017" ref-type="bibr">Felger et al., 2016</xref>). Administration of dopaminergic
drugs results in reversal of anhedonia symptoms in animals exposed to inflammatory cytokines
(<xref rid="CIT0016" ref-type="bibr">Felger, 2017</xref>; <xref rid="CIT0018" ref-type="bibr">Felger and Treadway, 2017</xref>). Similarly, use of bupropion, an
antidepressant medication that inhibits dopamine reuptake (<xref rid="CIT0004" ref-type="bibr">Ascher et al., 1995</xref>), has been shown to reduce the levels of
proinflammatory cytokines (interferon gamma and tumor necrosis factor alpha) after
lipopolysaccharide activation in mice (<xref rid="CIT0006" ref-type="bibr">Brustolim et al.,
2006</xref>). In contrast, administration of SSRIs in rodents has been shown to increase
levels of inflammatory cytokines (IL-1beta, IL-6, interferon gamma, and tumor necrosis
factor alpha) in the frontal cortex (<xref rid="CIT0054" ref-type="bibr">Warner-Schmidt et
al., 2011</xref>). In human studies, treatment with SSRIs has been shown to reduce serum
IL-6 and IL-1beta levels (<xref rid="CIT0020" ref-type="bibr">Hannestad et al.,
2011</xref>). In summary, peripheral inflammation can cause BBB disruption/dysfunction,
thereby increasing PDGF levels and promoting neuroinflammation. Resultant reduction in CNS
dopamine and symptoms of anhedonia can be reversed by administration of dopaminergic drug.
Thus, we hypothesize that elevated PDGF can serve as a treatment selection biomarker for
dopaminergic antidepressants by identifying depressed patients more likely to experience
improvement in anhedonia as well as overall depression severity. This addresses an urgent
need to identify moderators of treatment response to improve outcomes (<xref rid="CIT0044" ref-type="bibr">Trivedi, 2013</xref>, <xref rid="CIT0045" ref-type="bibr">2016</xref>; <xref rid="CIT0049" ref-type="bibr">Trivedi et al., 2016</xref>).</p><p>The primary aim of this report is to test the hypothesis that elevated baseline levels of
PDGF predict better treatment outcomes with bupropion vs other antidepressant medications.
We included other growth factors in this panel, as inflammatory markers have been shown to
stimulate release of growth factors (<xref rid="CIT0021" ref-type="bibr">Honorati et al.,
2006</xref>). Using data from the Combining Medications to Enhance Depression Outcomes
(CO-MED) trial, which compared escitalopram plus placebo, bupropion plus escitalopram, and
venlafaxine plus mirtazapine treatment arms, we (1) tested for differential treatment
outcomes among the 3 treatment arms based on pretreatment PDGF level as well as other growth
factors, and (2) evaluated if changes in anhedonia accounted for greater symptomatic
improvement in depressed patients with higher PDGF levels.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s3"><title>Study Overview</title><p>Data for this report were obtained from the CO-MED trial, which has been described in
detail by Rush et al. (<xref rid="CIT0037" ref-type="bibr">Rush et al., 2011</xref>).
Participants (n=665) were randomly assigned after stratification for site to the following
treatment arms: SSRI monotherapy (escitalopram plus placebo), bupropion-SSRI combination
(sustained-release [SR] bupropion plus escitalopram), and venlafaxine-mirtazapine
combination (extended-release [XR] venlafaxine plus mirtazapine). The analytic sample of
this report includes a subset of CO-MED trial participants who provided plasma samples at
baseline. Baseline plasma was collected as part of a separate add-on biomarker study,
which was optional and required an additional consent. Hence, all subjects in this report
provided a written informed consent for participation in the main trial as well as an
additional optional consent for the biomarker collection. Thus, the number of plasma
samples (n=166) collected at baseline was a subset of the total number of CO-MED trial
participants (n=665). Those participants who did not provide plasma (n=499) at baseline
were younger (mean age=44.51 years vs 42.11, <italic>P</italic> =.03) and had lower use of
statin medication (20.5% vs 13.6%, <italic>P</italic>=.03) compared with the analytic
sample of this report but did not differ on any other baseline clinical and
sociodemographic features (<xref rid="CIT0023a" ref-type="bibr">Jha et al. 2017a</xref>).
Additionally, as participation in the continuation phase of CO-MED was censured for those
participants with inadequate response (<xref rid="CIT0037" ref-type="bibr">Rush et al.,
2011</xref>), we restricted the analyses only to the acute-phase visits (baseline and
weeks 1, 2, 4, 6, 8, 10, and 12). The CO-MED trial used broad inclusion and exclusion
criteria (fully listed at <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00590863">https://clinicaltrials.gov/ct2/show/NCT00590863</ext-link>) while recruiting from
psychiatric and primary care clinics that were chosen to ensure adequate minority
representation and a diverse participant group (<xref rid="CIT0037" ref-type="bibr">Rush
et al., 2011</xref>). The trial was reviewed and approved by the Institutional Review
Boards at UT Southwestern Medical Center at Dallas, the University of Pittsburgh Data
Coordinating Center, each participating regional center, and all relevant clinics.</p></sec><sec id="s4"><title>Medications</title><p>Participants in all 3 treatment arms received 2 types of pills in single blind fashion
(study personnel knew of both pill types, but participants knew only the first pill type).
Dosage adjustments were made during the first 8 weeks of participation using principles of
measurement-based care, with dose increases permitted only if side effects were tolerable
and depression severity was not adequately controlled. Dose escalation regime as well as
mean doses of medications in each treatment arm have been previously described in detail
by Rush et al. (<xref rid="CIT0037" ref-type="bibr">Rush et al., 2011</xref>).
Participants in the SSRI monotherapy treatment arm were started on escitalopram at 10 mg/d
and placebo was added at week 2 as the second pill type. At the end of 12 weeks, the mean
escitalopram dose was 17.6 mg/d and mean placebo dose was 1.4 pills/d. For the
bupropion-SSRI combination treatment arm, participants were started on 150 mg of bupropion
SR and titrated to 300 mg/d at week 1, and escitalopram 10 mg/d was added as the second
pill type at week 2. At the end of 12 weeks, mean bupropion SR dose was 324.0 mg/d and
mean escitalopram dose was 14.0 mg/d. Participants in the venlafaxine-mirtazapine
treatment arm were started on venlafaxine XR, which was titrated from 37.5 mg/d to 150
mg/d at week 1 visit, and mirtazapine 15 mg/d was added at week 2 as the second pill type.
At the end of 12 weeks, the mean venlafaxine XR dose was 207.6 mg/d and mean mirtazapine
dose was 25.3 mg/d. Dose adjustments employed measurement-based care principles previously
used in large-scale clinical trials (<xref rid="CIT0035" ref-type="bibr">Trivedi et al.,
2006b</xref>).</p></sec><sec id="s5"><title>Assessments</title><p>At baseline, participants provided sociodemographic information. At baseline and all
treatment visits, participants filled out the 16-item Quick Inventory of Depressive
Symptomatology &#x02013; Self-Report (QIDS-SR) scale and Frequency, Intensity, and Burden of Side
Effect Rating Scale (FIBSER).</p><sec id="s6"><title>QIDS-SR</title><p>This commonly used scale has 16 items, each of which includes 4 choices that are scored
from 0 to 3. A total score is calculated from 9 of these 16 items (consistent with the 9
criterion symptom domains of major depressive disorder [MDD]) leading to a range of 0 to
27 (<xref rid="CIT0033" ref-type="bibr">Rush et al., 2003</xref>). Both measures
correlate highly (0.86&#x02013;0.93) with Hamilton Rating Score for Depression (<xref rid="CIT0034" ref-type="bibr">Rush et al., 2006a</xref>). In previous reports, the
reported Cronbach&#x02019;s &#x003b1; of QIDS-SR has ranged from 0.86 to 0.87 (<xref rid="CIT0033" ref-type="bibr">Rush et al., 2003</xref>, <xref rid="CIT0034" ref-type="bibr">2006a</xref>; <xref rid="CIT0046" ref-type="bibr">Trivedi et al., 2004</xref>). In
the CO-MED trial, the QIDS-SR served as the primary depression symptom severity outcome
measure.</p></sec><sec id="s7"><title>Inventory of Depressive Symptomatology Clinician Rated (IDS-C)</title><p>Of the 30 items of IDS-C (each item has 4 choices which are scored from 0 to 3), 28
items are summed to generate a total score (range 0 to 84), which correlates very highly
(Pearson&#x02019;s moment correlation = 0.95) with the 17-item Hamilton Rating Score for
Depression (<xref rid="CIT0032" ref-type="bibr">Rush et al., 1996</xref>). In previous
reports, the Cronbach&#x02019;s &#x003b1; of IDS-C has ranged from 0.67 to 0.94 (<xref rid="CIT0032" ref-type="bibr">Rush et al., 1996</xref>; <xref rid="CIT0046" ref-type="bibr">Trivedi et
al., 2004</xref>). Anhedonia, as measured by a subscale of 3 items of IDS-C, has been
shown to compare favorably to the Snaith-Hamilton Pleasure Scale (<xref rid="CIT0041" ref-type="bibr">Snaith et al., 1995</xref>) and was used as outcome for this report
(<xref rid="CIT0017" ref-type="bibr">Felger et al., 2016</xref>).</p></sec><sec id="s8"><title>FIBSER</title><p>This commonly used side effect rating scale was initially developed to document the
frequency, intensity, and burden of side effects in the large (n=4041) multisite
Sequenced Treatment Alternatives to Relieve Depression study (<xref rid="CIT0055" ref-type="bibr">Wisniewski et al., 2006</xref>). The 3 items of this self-report measure
are rated on a scale of 0 to 6, with higher numbers reflecting greater severity of side
effects. The Cronbach&#x02019;s &#x003b1; of FIBSER in Sequenced Treatment Alternatives to Relieve
Depression ranged from 0.91 to 0.93 at different study visits (weeks 2, 4, 6, 9, 12, and
14) (<xref rid="CIT0055" ref-type="bibr">Wisniewski et al., 2006</xref>). The sum of 3
items has been used as an overall score of FIBSER (<xref rid="CIT0003" ref-type="bibr">Schatzberg et al., 2015</xref>).</p></sec></sec><sec id="s9"><title>Measurement of PDGF and Other Growth Factors</title><p>Plasma samples extracted from CO-MED trial participants (n=166) were transported
overnight to the Biologic Core of National Institute of Mental Health Repository and
Genomics Resource (NIMH RGR) for storage at -80&#x000b0;C. All samples for this report were
obtained from the NIMH RGR core. Levels of PDGF and other biomarkers were measured in all
samples at the same time, blinded to treatment allocation and outcomes by the Microarray
Core at UT Southwestern Medical Center using the Bioplex Pro human cytokine standard
27-plex kit (Bio-Rad Laboratories) with a Bio-plex 200 instrument that was equipped with
Bio-Plex Manager software, version 6.0 (Bio-Rad Laboratory). This 27-plex kit measures
PDGF, FGF-basic, and G-CSF, which were interpreted only if the intra- and inter-assay
coefficients of variation were &#x0003c;10% of detection limits (or precision range) specified
by manufacturer. The levels of PDGF, FGF-basic, and G-CSF were expressed in pg/mL with
correction for 4-fold dilution using the standards provided in the kit (Bio-Rad
Laboratory).</p></sec><sec id="s10"><title>Statistical Analyses</title><p>We used log-transformation for biomarkers that were not normally distributed. We used
separate repeated-measures mixed model analyses with QIDS-SR, anhedonia, and FIBSER total
score to test for treatment arm-by-baseline biomarker interaction for PDGF, FGF-basic, and
G-CSF after controlling for select baseline covariates (age, gender, and BMI) using
methods outlined by Uher et al. (<xref rid="CIT0050" ref-type="bibr">Uher et al.,
2014</xref>). A significant treatment arm-by-biomarker interaction suggests that the
outcomes in 3 treatment arms differed on the basis of baseline biomarker levels. Hence,
this was the interaction of interest in our study. When interaction was statistically
significant, we used stratified analyses for each treatment arm to quantify the change,
including calculation of effect sizes, in outcomes (QIDS-SR, anhedonia, and/or FIBSER)
based on biomarker levels, consistent with the approach of Uher et al. (<xref rid="CIT0050" ref-type="bibr">Uher et al., 2014</xref>). To visualize the treatment
arm-by-biomarker interaction, we plotted the average estimates of dependent variable
(QIDS-SR, anhedonia, and/or FIBSER) over the course of acute-phase of CO-MED trial
(including baseline) against the baseline plasma biomarker level. To evaluate if changes
in anhedonia accounted for greater symptomatic improvement, we included anhedonia score at
each available visit as a covariate in the stratified analyses for treatment arm with a
significant effect of baseline biomarker. We used SAS version 9.3 for all our analyses and
set the threshold of significance at <italic>P</italic> &#x0003c;.05.</p></sec></sec><sec id="s11"><title>Results</title><p>Plasma samples were available from 166 participants who constitute the analytic sample of
this report. The mean (SD) concentrations of PDGF, FGF-basic, and G-CSF at baseline were
1630.95 (1249.65) pg/mL, 103.94 (27.39) pg/mL, and 96.98 (29.40) pg/mL, respectively.
Participants in all 3 treatment arms did not differ on sociodemographic and clinical
variables or biomarkers, except participants in the venlafaxine-mirtazapine combination, who
had a significantly lower age, as shown in <xref ref-type="table" rid="T1">Table
1</xref>.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Sociodemographic Characteristics and Clinical and Biological Markers of CO-MED Trial
Participants (n=166) with Plasma Available at Baseline</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" colspan="2" rowspan="1">SSRI monotherapy</th><th align="left" valign="bottom" colspan="2" rowspan="1">Bupropion-SSRI</th><th align="left" valign="bottom" colspan="2" rowspan="1">Venlafaxine-mirtazapine</th><th valign="bottom" rowspan="1" colspan="1"/><th valign="bottom" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td rowspan="1" colspan="1">Number</td><td rowspan="1" colspan="1">51</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">55</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Categorical variables</td><td rowspan="1" colspan="1">n</td><td rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1">n</td><td rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1">n</td><td rowspan="1" colspan="1">%</td><td rowspan="1" colspan="1">&#x003c7;<sup>2</sup> (df)</td><td rowspan="1" colspan="1">
<italic>P</italic> value</td></tr><tr><td rowspan="1" colspan="1">Male sex</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">31.4</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">29.1</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">28.3</td><td rowspan="1" colspan="1">0.13 (2)</td><td rowspan="1" colspan="1">.94</td></tr><tr><td rowspan="1" colspan="1">White race</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">52.9</td><td rowspan="1" colspan="1">39</td><td rowspan="1" colspan="1">70.9</td><td rowspan="1" colspan="1">41</td><td rowspan="1" colspan="1">68.3</td><td rowspan="1" colspan="1">4.60 (4)</td><td rowspan="1" colspan="1">.29</td></tr><tr><td rowspan="1" colspan="1">Hispanic ethnicity</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">15.7</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">12.7</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">1.13 (2)</td><td rowspan="1" colspan="1">.57</td></tr><tr><td rowspan="1" colspan="1">Income &#x0003c;$2000/month</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">56.5</td><td rowspan="1" colspan="1">29</td><td rowspan="1" colspan="1">61.7</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">64.9</td><td rowspan="1" colspan="1">1.26 (4)</td><td rowspan="1" colspan="1">.87</td></tr><tr><td rowspan="1" colspan="1">Education &#x0003c;12 y</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">7.8</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">20.0</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">4.20 (4)</td><td rowspan="1" colspan="1">.38</td></tr><tr><td rowspan="1" colspan="1">Presence of anxious features</td><td rowspan="1" colspan="1">33</td><td rowspan="1" colspan="1">64.7</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">78.2</td><td rowspan="1" colspan="1">44</td><td rowspan="1" colspan="1">73.3</td><td rowspan="1" colspan="1">2.45 (2)</td><td rowspan="1" colspan="1">.29</td></tr><tr><td rowspan="1" colspan="1">Presence of atypical features</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">19.6</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">21.8</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">21.7</td><td rowspan="1" colspan="1">0.10 (2)</td><td rowspan="1" colspan="1">.95</td></tr><tr><td rowspan="1" colspan="1">Presence of melancholic features</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">27.5</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">30.9</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">33.3</td><td rowspan="1" colspan="1">0.45 (2)</td><td rowspan="1" colspan="1">.80</td></tr><tr><td rowspan="1" colspan="1">Presence of suicidal ideation</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">52.9</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">56.4</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">60.0</td><td rowspan="1" colspan="1">0.56 (2)</td><td rowspan="1" colspan="1">.76</td></tr><tr><td rowspan="1" colspan="1">Depression onset before age 18</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">35.3</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">43.6</td><td rowspan="1" colspan="1">25</td><td rowspan="1" colspan="1">41.7</td><td rowspan="1" colspan="1">0.83 (2)</td><td rowspan="1" colspan="1">.66</td></tr><tr><td valign="bottom" rowspan="1" colspan="1">Continuous variables</td><td valign="bottom" rowspan="1" colspan="1">Mean</td><td valign="bottom" rowspan="1" colspan="1">SD</td><td valign="bottom" rowspan="1" colspan="1">Mean</td><td valign="bottom" rowspan="1" colspan="1">SD</td><td valign="bottom" rowspan="1" colspan="1">Mean</td><td valign="bottom" rowspan="1" colspan="1">SD</td><td valign="bottom" rowspan="1" colspan="1">F value (df)</td><td valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> value</td></tr><tr><td rowspan="1" colspan="1">Age in years</td><td rowspan="1" colspan="1">47.0</td><td rowspan="1" colspan="1">11.8</td><td rowspan="1" colspan="1">46.3</td><td rowspan="1" colspan="1">12.1</td><td rowspan="1" colspan="1">40.8</td><td rowspan="1" colspan="1">11.2</td><td rowspan="1" colspan="1">4.92 (2)</td><td rowspan="1" colspan="1">.01</td></tr><tr><td rowspan="1" colspan="1">QIDS-SR</td><td rowspan="1" colspan="1">15.7</td><td rowspan="1" colspan="1">3.4</td><td rowspan="1" colspan="1">15.0</td><td rowspan="1" colspan="1">4.7</td><td rowspan="1" colspan="1">16.0</td><td rowspan="1" colspan="1">4.1</td><td rowspan="1" colspan="1">0.97 (2)</td><td rowspan="1" colspan="1">.38</td></tr><tr><td rowspan="1" colspan="1">Anhedonia (from IDS-C)</td><td rowspan="1" colspan="1">5.4</td><td rowspan="1" colspan="1">2.0</td><td rowspan="1" colspan="1">5.3</td><td rowspan="1" colspan="1">2.2</td><td rowspan="1" colspan="1">5.7</td><td rowspan="1" colspan="1">2.0</td><td rowspan="1" colspan="1">0.63 (2)</td><td rowspan="1" colspan="1">.53</td></tr><tr><td rowspan="1" colspan="1">Log of PDGF in pg/mL</td><td rowspan="1" colspan="1">7.1</td><td rowspan="1" colspan="1">0.8</td><td rowspan="1" colspan="1">7.2</td><td rowspan="1" colspan="1">0.7</td><td rowspan="1" colspan="1">7.1</td><td rowspan="1" colspan="1">0.7</td><td rowspan="1" colspan="1">0.37 (2)</td><td rowspan="1" colspan="1">.69</td></tr><tr><td rowspan="1" colspan="1">FGF-basic (pg/mL)</td><td rowspan="1" colspan="1">103.6</td><td rowspan="1" colspan="1">30.5</td><td rowspan="1" colspan="1">108.4</td><td rowspan="1" colspan="1">22.4</td><td rowspan="1" colspan="1">100.2</td><td rowspan="1" colspan="1">28.6</td><td rowspan="1" colspan="1">1.31 (2)</td><td rowspan="1" colspan="1">.27</td></tr><tr><td rowspan="1" colspan="1">Log of G-CSF in pg/mL</td><td rowspan="1" colspan="1">4.6</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">4.6</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">4.5</td><td rowspan="1" colspan="1">0.3</td><td rowspan="1" colspan="1">0.97 (2)</td><td rowspan="1" colspan="1">.38</td></tr></tbody></table><table-wrap-foot><fn id="fn-01"><p>Abbreviations: bupropion-SSRI, combination of sustained-release bupropion plus
escitalopram; CO-MED, Combining Medications to Enhance Depression Outcomes; FGF,
fibroblast growth factor; G-CSF, granulocyte colony stimulating factor; IDS-C,
Inventory of Depressive Symptomatology Clinician-rated; PDGF, platelet derived growth
factor; QIDS-SR, Quick Inventory of Depressive Symptomatology Self-Report; SSRI
monotherapy, escitalopram plus placebo; venlafaxine-mirtazapine, combination of
extended-release venlafaxine plus mirtazapine.</p></fn></table-wrap-foot></table-wrap><p>In separate mixed-model analyses for QIDS-SR, anhedonia, and FIBSER, we found that PDGF had
a significant treatment-arm-by-biomarker interaction for QIDS-SR (F=3.50, df=2, 157,
<italic>P</italic>=.033) and anhedonia (F=4.95, df=2, 157, <italic>P</italic>=.008) (also
see <xref ref-type="table" rid="T2">Table 2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Moderating Effects of PDGF and Other Growth Factors on Overall Depression Severity,
Anhedonia, and Side Effects in CO-MED Trial</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" colspan="3" rowspan="1">Depression severity*</th><th align="left" valign="bottom" colspan="3" rowspan="1">Anhedonia*</th><th align="left" valign="bottom" colspan="3" rowspan="1">Side effects*</th></tr><tr><th valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">F</th><th align="left" valign="bottom" rowspan="1" colspan="1">df</th><th align="left" valign="bottom" rowspan="1" colspan="1">P</th><th align="left" valign="bottom" rowspan="1" colspan="1">F</th><th align="left" valign="bottom" rowspan="1" colspan="1">df</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">F</th><th align="left" valign="bottom" rowspan="1" colspan="1">df</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">PDGF</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Treatment arm</td><td rowspan="1" colspan="1">3.36</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">
<bold>.037</bold>
</td><td rowspan="1" colspan="1">4.79</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">
<bold>.01</bold>
</td><td rowspan="1" colspan="1">0.60</td><td rowspan="1" colspan="1">2, 148</td><td rowspan="1" colspan="1">.55</td></tr><tr><td rowspan="1" colspan="1">Log of baseline PDGF level</td><td rowspan="1" colspan="1">0.81</td><td rowspan="1" colspan="1">1, 157</td><td rowspan="1" colspan="1">.37</td><td rowspan="1" colspan="1">0.09</td><td rowspan="1" colspan="1">1, 157</td><td rowspan="1" colspan="1">.77</td><td rowspan="1" colspan="1">2.71</td><td rowspan="1" colspan="1">1, 148</td><td rowspan="1" colspan="1">.10</td></tr><tr><td rowspan="1" colspan="1">Log-PDGF-by-treatment arm interaction</td><td rowspan="1" colspan="1">3.50</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">
<bold>.033</bold>
</td><td rowspan="1" colspan="1">4.95</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">
<bold>.008</bold>
</td><td rowspan="1" colspan="1">0.83</td><td rowspan="1" colspan="1">2, 148</td><td rowspan="1" colspan="1">.44</td></tr><tr><td rowspan="1" colspan="1">FGF-basic</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Treatment arm</td><td rowspan="1" colspan="1">0.89</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">.41</td><td rowspan="1" colspan="1">1.25</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">.29</td><td rowspan="1" colspan="1">0.83</td><td rowspan="1" colspan="1">2, 148</td><td rowspan="1" colspan="1">.44</td></tr><tr><td rowspan="1" colspan="1">Baseline FGF-basic level</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">1, 157</td><td rowspan="1" colspan="1">.86</td><td rowspan="1" colspan="1">1.22</td><td rowspan="1" colspan="1">1, 157</td><td rowspan="1" colspan="1">.27</td><td rowspan="1" colspan="1">1.32</td><td rowspan="1" colspan="1">1, 148</td><td rowspan="1" colspan="1">.25</td></tr><tr><td rowspan="1" colspan="1">FGF-basic-by-treatment arm interaction</td><td rowspan="1" colspan="1">1.22</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">.30</td><td rowspan="1" colspan="1">1.09</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">.34</td><td rowspan="1" colspan="1">0.78</td><td rowspan="1" colspan="1">2, 148</td><td rowspan="1" colspan="1">.46</td></tr><tr><td rowspan="1" colspan="1">G-CSF</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Treatment arm</td><td rowspan="1" colspan="1">0.52</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">.60</td><td rowspan="1" colspan="1">1.38</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">.25</td><td rowspan="1" colspan="1">1.82</td><td rowspan="1" colspan="1">2, 148</td><td rowspan="1" colspan="1">.17</td></tr><tr><td rowspan="1" colspan="1">Log of baseline G-CSF level</td><td rowspan="1" colspan="1">1.24</td><td rowspan="1" colspan="1">1, 157</td><td rowspan="1" colspan="1">.27</td><td rowspan="1" colspan="1">10.02</td><td rowspan="1" colspan="1">1, 157</td><td rowspan="1" colspan="1">.002</td><td rowspan="1" colspan="1">0.40</td><td rowspan="1" colspan="1">1, 148</td><td rowspan="1" colspan="1">.53</td></tr><tr><td rowspan="1" colspan="1">Log-G-CSF-by-treatment arm interaction</td><td rowspan="1" colspan="1">0.53</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">.59</td><td rowspan="1" colspan="1">1.13</td><td rowspan="1" colspan="1">2, 157</td><td rowspan="1" colspan="1">.33</td><td rowspan="1" colspan="1">2.21</td><td rowspan="1" colspan="1">2, 148</td><td rowspan="1" colspan="1">.11</td></tr></tbody></table><table-wrap-foot><fn id="fn-02"><p>Abbreviations: CO-MED, Combining Medications to Enhance Depression Outcomes; F, F
value from the mixed model analyses; FIBSER, Frequency, Intensity, and Burden of Side
Effects Rating Scale; FGF, fibroblast growth factor; G-CSF, granulocyte colony
stimulating factor; IDS-C, Inventory of Depressive Symptomatology Clinician-rated;
PDGF, platelet derived growth factor; QIDS-SR, Quick Inventory of Depressive
Symptomatology Self-Report.</p></fn><fn id="fn-03"><p>Anhedonia was measured by the 3-item anhedonia-subscale of the IDS-C and FIBSER.</p></fn><fn id="fn-04"><p>Treatment arms include: escitalopram plus placebo, combination of sustained-release
bupropion plus escitalopram, and combination of extended-release venlafaxine plus
mirtazapine.</p></fn><fn id="fn-05"><p>* Gender, age, BMI, visit, and visit-by-treatment arm interaction were covariates in
all mixed model analyses.</p></fn></table-wrap-foot></table-wrap><p>In subsequent analyses stratified by treatment arm, we found that higher log of PDGF levels
at baseline predicted lower depression severity over the course of acute-phase treatment
only in bupropion-SSRI combination treatment arm (Cohen&#x02019;s d effect size=0.70, est.= -1.86,
SE= 0.73, <italic>P</italic>=.015) and not in SSRI monotherapy (Cohen&#x02019;s d effect size=0.04,
est.= 0.10, SE=0.73, <italic>P</italic>=.89) or venlafaxine-mirtazapine combination
treatment arm (Cohen&#x02019;s d effect size=0.03, est. =0.08, SE=0.76, <italic>P</italic>=.91)
(also see <xref ref-type="table" rid="T3">Table 3</xref>). As shown in <xref ref-type="fig" rid="F2">Figure 2</xref>, we found that QIDS-SR (averaged over acute-phase including
baseline) decreased with increasing levels of PDGF at baseline in bupropion-SSRI combination
(correlation coefficient = -0.66) but not in SSRI monotherapy (correlation coefficient =
0.08) and venlafaxine-mirtazapine combination (correlation coefficient = 0.17) treatment
arms.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Differential Effect of Platelet-Derived Growth Factor (PDGF) on Depression Severity and
Anhedonia Based on Treatment Arm in CO-MED Trial</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Estimate*</th><th align="left" valign="bottom" rowspan="1" colspan="1">SE</th><th align="left" valign="bottom" rowspan="1" colspan="1">F value</th><th align="left" valign="bottom" rowspan="1" colspan="1">df</th><th align="left" valign="bottom" rowspan="1" colspan="1">Effect size</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic>P</italic> Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Depression severity</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SSRI monotherapy</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">0.73</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">1, 46</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">.89</td></tr><tr><td rowspan="1" colspan="1">Bupropion-SSRI</td><td rowspan="1" colspan="1">-1.86</td><td rowspan="1" colspan="1">0.73</td><td rowspan="1" colspan="1">6.37</td><td rowspan="1" colspan="1">1, 50</td><td rowspan="1" colspan="1">
<bold>0.70</bold>
</td><td rowspan="1" colspan="1">
<bold>.015</bold>
</td></tr><tr><td rowspan="1" colspan="1">Venlafaxine-mirtazapine</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">0.76</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">1, 55</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">.91</td></tr><tr><td rowspan="1" colspan="1">Anhedonia</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">SSRI monotherapy</td><td rowspan="1" colspan="1">0.72</td><td rowspan="1" colspan="1">0.37</td><td rowspan="1" colspan="1">3.87</td><td rowspan="1" colspan="1">1, 46</td><td rowspan="1" colspan="1">0.57</td><td rowspan="1" colspan="1">.06</td></tr><tr><td rowspan="1" colspan="1">Bupropion-SSRI</td><td rowspan="1" colspan="1">-0.71</td><td rowspan="1" colspan="1">0.30</td><td rowspan="1" colspan="1">5.62</td><td rowspan="1" colspan="1">1, 50</td><td rowspan="1" colspan="1">
<bold>0.66</bold>
</td><td rowspan="1" colspan="1">
<bold>.02</bold>
</td></tr><tr><td rowspan="1" colspan="1">Venlafaxine-mirtazapine</td><td rowspan="1" colspan="1">0.10</td><td rowspan="1" colspan="1">0.34</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">1, 55</td><td rowspan="1" colspan="1">0.08</td><td rowspan="1" colspan="1">.78</td></tr></tbody></table><table-wrap-foot><fn id="fn-06"><p>Abbreviations: bupropion-SSRI, combination of sustained-release bupropion plus
escitalopram; CO-MED, Combining Medications to Enhance Depression Outcomes; SSRI
monotherapy, escitalopram plus placebo; venlafaxine-mirtazapine, combination of
extended-release venlafaxine plus mirtazapine.</p></fn><fn id="fn-07"><p>Estimate obtained from solution for fixed effects in mixed model analyses and
represents the estimated difference in self-reported depression severity as measured
by Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) and anhedonia as
measured by the 3-item anhedonia-subscale of the Inventory of Depressive
Symptomatology Clinician-rated (IDS-C) for 1 unit difference in log of PGDF in each
treatment arm.</p></fn></table-wrap-foot></table-wrap><fig fig-type="figure" id="F2" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Depression severity during acute-phase of Combining Medications to Enhance Depression
Outcomes (CO-MED) trial based on baseline plasma platelet derived growth factor (PDGF)
level. Average Quick Inventory of Depressive Symptomatology &#x02013; Self-Report (QIDS-SR) was
obtained from mixed model analyses of all available visits (least square means) during
the acute-phase of CO-MED trial for the following three treatment arms: selective
serotonin reuptake inhibitor (SSRI) monotherapy, bupropion-SSRI combination, and
venlafaxine-mirtazapine combination. PDGF is platelet-derived growth factor.</p></caption><graphic xlink:href="pyx06002"/></fig><p>In stratified analyses of change in anhedonia based on PDGF levels, we found that higher
levels at baseline predicted lower severity of anhedonia over the course of acute phase with
bupropion-SSRI combination (Cohen&#x02019;s d effect size=0.66, <italic>P</italic>=.015) but not
with SSRI monotherapy (Cohen&#x02019;s d effect size=0.57, <italic>P</italic>=.06) or
venlafaxine-mirtazapine combination (Cohen&#x02019;s d effect size=0.08, <italic>P</italic>=.78)
treatment arms (also see <xref ref-type="table" rid="T3">Table 3</xref>). As shown in <xref ref-type="fig" rid="F3">Figure 3</xref>, we found that higher baseline levels of PDGF were
associated with lower severity of anhedonia (averaged over acute-phase including baseline)
with bupropion-SSRI combination (correlation coefficient= -0.57). Conversely, higher
baseline PDGF levels were associated with smaller reductions in anhedonia with SSRI
monotherapy (correlation coefficient of anhedonia averaged during acute-phase and log of
PDGF= 0.52) and venlafaxine-mirtazapine (correlation coefficient of anhedonia averaged
during acute-phase and log of PDGF= 0.24).</p><fig fig-type="figure" id="F3" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Severity of anhedonia during acute-phase of Combining Medications to Enhance Depression
Outcomes (CO-MED) trial based on baseline plasma platelet derived growth factor (PDGF)
level. Average score of anhedonia subscale of Inventory of Depressive Symptomatology
Clinician Rated (IDS-C) was obtained from mixed model analyses of all available visits
(least square means) during the acute-phase of CO-MED trial for the following three
treatment arms: selective serotonin reuptake inhibitor (SSRI) monotherapy,
bupropion-SSRI combination, and venlafaxine-mirtazapine combination.</p></caption><graphic xlink:href="pyx06003"/></fig><p>We included anhedonia scores at each visit as a covariate to evaluate if improvement in
anhedonia accounted for improvement in depression severity in the bupropion-SSRI treatment
arm, and found that change in depression severity with one unit increase in log of PDGF at
baseline was no longer statistically significant (Cohen&#x02019;s d effect size=0.52, est.= -1.17,
SE=0.63, F=3.49, df=1, 50, <italic>P</italic>=.07) after controlling for anhedonia.</p></sec><sec id="s12"><title>Discussion</title><p>We have for the first time found in a large sample of depressed patients that elevated
levels of PDGF at baseline were selectively associated with greater reduction in overall
depression severity and anhedonia with bupropion-SSRI combination treatment, but not in
those treated with SSRI monotherapy or venlafaxine-mirtazapine combination. We also found
that improvement of anhedonia accounted for the baseline PDGF-based improvement in
depression severity with bupropion-SSRI. To our knowledge, this is the first study
evaluating the moderator effect of baseline levels of PDGF on antidepressant treatment
outcomes.</p><p>Our findings are consistent with the potential role of drugs modulating dopaminergic
neurotransmission in treatment of depression with an exciting application of using
pramipexole, a dopamine receptor agonist which was reportedly effective in a recent case
series of treatment resistant depression patients (<xref rid="CIT0014" ref-type="bibr">Fawcett et al., 2016</xref>). Thus, the findings of this study have immediate application
for clinical practice. Our findings also have significant implications for research as we
attempt to understand the precise mechanism of how neuroinflammation causes depression and
how best to modify treatment in those presenting with neuroinflammation. With initial
antidepressant treatment, over two-thirds of MDD patients continue to have significant
depressive symptoms (<xref rid="CIT0048" ref-type="bibr">Rush et al., 2006b</xref>, 200bc;
<xref rid="CIT0034" ref-type="bibr">Trivedi et al., 2006a</xref>, <xref rid="CIT0035" ref-type="bibr">2006b</xref>). No clinical variables (such as baseline depression severity,
atypical features, melancholic features, and obesity) or reliable and valid biomarkers
(including imaging and electrophysiological markers) have proven to be useful in identifying
subgroups of MDD patients who will respond differently to currently available antidepressant
medications (<xref rid="CIT0037" ref-type="bibr">Rush et al., 2011</xref>; <xref rid="CIT0003" ref-type="bibr">Arnow et al., 2015</xref>). Hence, our findings address the
urgent need to identify biological markers at baseline that can facilitate selection amongst
currently available antidepressant treatments (<xref rid="CIT0043" ref-type="bibr">Toups and
Trivedi, 2012</xref>).</p><p>Our study has several limitations. This is a secondary analysis of participants in the
CO-MED trial. As identifying biological markers as moderators of treatment outcome was not
the primary outcome of the CO-MED trial, we did not a priori test the power needed to detect
moderator effects of PDGF. However, the moderator effect sizes in our study are large
(Cohen&#x02019;s d &#x0003e; 0.5) (<xref rid="CIT0009" ref-type="bibr">Cohen, 1988</xref>) and compare
favorably with the moderator effect size for treatment selection in previous studies (<xref rid="CIT0052" ref-type="bibr">Wallace et al., 2013</xref>, <xref rid="CIT0053" ref-type="bibr">2017</xref>). Additionally, the immune system is a complex interplay of
multiple factors and therefore, reverse translation through animal models will be necessary
to confirm these findings. Apathy, or lack of motivation, may occur in depressed patients
taking SSRIs such as escitalopram (<xref rid="CIT0015" ref-type="bibr">FDA, 2017</xref>) and
reportedly improves with bupropion treatment (<xref rid="CIT0010" ref-type="bibr">Corcoran
et al., 2004</xref>). Apathy significantly correlates with anhedonia (<xref rid="CIT0001" ref-type="bibr">Ang et al., 2017</xref>) and is described in context of
social inactivity in depressed patients (<xref rid="CIT0028" ref-type="bibr">Marin,
1990</xref>). Lack of systematic evaluation of SSRI-emergent apathy or changes in apathy
with treatment is another limitation of this report. Further, as the CO-MED trial permitted
dose adjustment of antidepressant medications per MBC guidelines, it is uncertain as to how
these dose adjustments affected the differential treatment response based on baseline PDGF
levels. In light of these limitations, findings from this study should be considered
preliminary and need replication and extension. Additionally, by design in the CO-MED trial,
each treatment arm contained a medication with serotonergic activity that could restrict the
interpretation of these findings specifically to bupropion.</p><p>In conclusion, in our study, we found strong evidence for the first time that elevated
levels of PDGF are selectively associated with better clinical outcomes, mediated
predominantly by anhedonia improvement, in depressed patients treated with a combination of
bupropion and escitalopram compared with those treated with either escitalopram monotherapy
or a combination of venlafaxine and mirtazapine.</p></sec><sec id="s105"><title>Statement of Interest</title><p>Drs Jha, Minhajuddin, and Gadad have no potential conflicts of interest. Dr Trivedi is or
has been an advisor/consultant and received fees from: Alkermes, AstraZeneca, Cerecor, Eli
Lilly &#x00026; Company, Lundbeck, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Pfizer
Inc., SHIRE Development, and Takeda. In addition, he has received grants/research support
from National Institute of Mental Health and National Institute on Drug Abuse.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank the clinical staff at each clinical site for their assistance with this
project, all the study participants, and Jennifer Furman, PhD, for administrative
support.</p><p>This work was supported by the National Institute of Mental Health (N01 MH-90003 to M. H.
Trivedi and A. J. Rush). This work was also supported in part through the Center for
Depression Research and Clinical Care at UT Southwestern (principal investigator: Madhukar
H. Trivedi, MD), The Hersh Foundation, and The Jordan Harris Foundation. Forest
Pharmaceuticals, GlaxoSmithKline, Organon, and Wyeth Pharmaceuticals provided medications
for CO-MED trial at no cost. The content of this publication does not necessarily reflect
the views or policies of the U.S. Department of Health and Human Services, nor does mention
of trade names, commercial products, or organizations imply endorsement by the U.S.
government. NIMH had no role in the drafting or review of the manuscript or in the
collection or analysis of the data.</p></ack><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ang</surname><given-names>Y-S</given-names></name>,
<name name-style="western"><surname>Lockwood</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Apps</surname><given-names>MAJ</given-names></name>,
<name name-style="western"><surname>Muhammed</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Husain</surname><given-names>M</given-names></name></person-group>
(<year>2017</year>) <article-title>Distinct subtypes of apathy revealed by the apathy
motivation index</article-title>. <source>PLoS
One</source><volume>12</volume>:<fpage>e0169938</fpage>.<pub-id pub-id-type="pmid">28076387</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Arimura</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Ago</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Kamouchi</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Nakamura</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Ishitsuka</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Kuroda</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Sugimori</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Ooboshi</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Sasaki</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Kitazono</surname><given-names>T</given-names></name></person-group>
(<year>2012</year>) <article-title>PDGF receptor beta signaling in pericytes following
ischemic brain injury</article-title>. <source>Curr Neurovasc
Res</source><volume>9</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">22272762</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Arnow</surname><given-names>BA</given-names></name>,
<name name-style="western"><surname>Blasey</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Williams</surname><given-names>LM</given-names></name>,
<name name-style="western"><surname>Palmer</surname><given-names>DM</given-names></name>,
<name name-style="western"><surname>Rekshan</surname><given-names>W</given-names></name>,
<name name-style="western"><surname>Schatzberg</surname><given-names>AF</given-names></name>,
<name name-style="western"><surname>Etkin</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Kulkarni</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Luther</surname><given-names>JF</given-names></name>,
<name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name></person-group>
(<year>2015</year>) <article-title>Depression subtypes in predicting antidepressant
response: a report from the iSPOT-D trial</article-title>. <source>Am J
Psychiatry</source><volume>172</volume>:<fpage>743</fpage>&#x02013;<lpage>750</lpage>.<pub-id pub-id-type="pmid">25815419</pub-id></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ascher</surname><given-names>JA</given-names></name>,
<name name-style="western"><surname>Cole</surname><given-names>JO</given-names></name>,
<name name-style="western"><surname>Colin</surname><given-names>JN</given-names></name>,
<name name-style="western"><surname>Feighner</surname><given-names>JP</given-names></name>,
<name name-style="western"><surname>Ferris</surname><given-names>RM</given-names></name>,
<name name-style="western"><surname>Fibiger</surname><given-names>HC</given-names></name>,
<name name-style="western"><surname>Golden</surname><given-names>RN</given-names></name>,
<name name-style="western"><surname>Martin</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Potter</surname><given-names>WZ</given-names></name>,
<name name-style="western"><surname>Richelson</surname><given-names>E</given-names></name><etal/></person-group>
(<year>1995</year>) <article-title>Bupropion: a review of its mechanism of
antidepressant activity</article-title>. <source>J Clin
Psychiatry</source><volume>56</volume>:<fpage>395</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">7665537</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Benedetti</surname><given-names>F</given-names></name>,
<name name-style="western"><surname>Poletti</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Hoogenboezem</surname><given-names>TA</given-names></name>,
<name name-style="western"><surname>Mazza</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Ambree</surname><given-names>O</given-names></name>,
<name name-style="western"><surname>de Wit</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Wijkhuijs</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Locatelli</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Bollettini</surname><given-names>I</given-names></name>,
<name name-style="western"><surname>Colombo</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Arolt</surname><given-names>V</given-names></name>,
<name name-style="western"><surname>Drexhage</surname><given-names>HA</given-names></name></person-group>
(<year>2016</year>) <article-title>Inflammatory cytokines influence measures of white
matter integrity in bipolar disorder</article-title>. <source>J Affect
Disord</source><volume>202</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27253210</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Brustolim</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Ribeiro-dos-Santos</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Kast</surname><given-names>RE</given-names></name>,
<name name-style="western"><surname>Altschuler</surname><given-names>EL</given-names></name>,
<name name-style="western"><surname>Soares</surname><given-names>MB</given-names></name></person-group>
(<year>2006</year>) <article-title>A new chapter opens in anti-inflammatory treatments:
the antidepressant bupropion lowers production of tumor necrosis factor-alpha and
interferon-gamma in mice</article-title>. <source>Int
Immunopharmacol</source><volume>6</volume>:<fpage>903</fpage>&#x02013;<lpage>907</lpage>.<pub-id pub-id-type="pmid">16644475</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bryleva</surname><given-names>EY</given-names></name>,
<name name-style="western"><surname>Keaton</surname><given-names>SA</given-names></name>,
<name name-style="western"><surname>Grit</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Madaj</surname><given-names>Z</given-names></name>,
<name name-style="western"><surname>Sauro-Nagendra</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Smart</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Halstead</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Achtyes</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Brundin</surname><given-names>L</given-names></name></person-group>
(<year>2017</year>) <article-title>The acute-phase mediator serum amyloid A is
associated with symptoms of depression and fatigue</article-title>. <source>Acta
Psychiatr
Scand</source><volume>135</volume>:<fpage>409</fpage>&#x02013;<lpage>418</lpage>.<pub-id pub-id-type="pmid">28374419</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cassidy-Bushrow</surname><given-names>AE</given-names></name>,
<name name-style="western"><surname>Peters</surname><given-names>RM</given-names></name>,
<name name-style="western"><surname>Johnson</surname><given-names>DA</given-names></name>,
<name name-style="western"><surname>Templin</surname><given-names>TN</given-names></name></person-group>
(<year>2012</year>) <article-title>Association of depressive symptoms with inflammatory
biomarkers among pregnant African-American women</article-title>. <source>J Reprod
Immunol</source><volume>94</volume>:<fpage>202</fpage>&#x02013;<lpage>209</lpage>.<pub-id pub-id-type="pmid">22386525</pub-id></mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>J</given-names></name></person-group> (<year>1988</year>) <source>Statistical power analysis for the behavioral
sciences</source>. <publisher-loc>Hillsdale, NJ</publisher-loc>:
<publisher-name>Lawrence Earlbaum Associates</publisher-name>,
pp<fpage>20</fpage>&#x02013;<lpage>26</lpage>.</mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Corcoran</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Wong</surname><given-names>ML</given-names></name>,
<name name-style="western"><surname>O&#x02019;Keane</surname><given-names>V</given-names></name></person-group>
(<year>2004</year>) <article-title>Bupropion in the management of
apathy</article-title>. <source>J
Psychopharmacol</source><volume>18</volume>:<fpage>133</fpage>&#x02013;<lpage>135</lpage>.<pub-id pub-id-type="pmid">15107198</pub-id></mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name></person-group> (<year>2008</year>) <article-title>TH17 cells in development: an updated
view of their molecular identity and genetic programming</article-title>. <source>Nat
Rev
Immunol</source><volume>8</volume>:<fpage>337</fpage>&#x02013;<lpage>348</lpage>.<pub-id pub-id-type="pmid">18408735</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dowlati</surname><given-names>Y</given-names></name>,
<name name-style="western"><surname>Herrmann</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Swardfager</surname><given-names>W</given-names></name>,
<name name-style="western"><surname>Liu</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Sham</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Reim</surname><given-names>EK</given-names></name>,
<name name-style="western"><surname>Lanctot</surname><given-names>KL</given-names></name></person-group>
(<year>2010</year>) <article-title>A meta-analysis of cytokines in major
depression</article-title>. <source>Biol
Psychiatry</source><volume>67</volume>:<fpage>446</fpage>&#x02013;<lpage>457</lpage>.<pub-id pub-id-type="pmid">20015486</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Eisenberger</surname><given-names>NI</given-names></name>,
<name name-style="western"><surname>Berkman</surname><given-names>ET</given-names></name>,
<name name-style="western"><surname>Inagaki</surname><given-names>TK</given-names></name>,
<name name-style="western"><surname>Rameson</surname><given-names>LT</given-names></name>,
<name name-style="western"><surname>Mashal</surname><given-names>NM</given-names></name>,
<name name-style="western"><surname>Irwin</surname><given-names>MR</given-names></name></person-group>
(<year>2010</year>) <article-title>Inflammation-induced anhedonia: endotoxin reduces
ventral striatum responses to reward</article-title>. <source>Biol
Psychiatry</source><volume>68</volume>:<fpage>748</fpage>&#x02013;<lpage>754</lpage>.<pub-id pub-id-type="pmid">20719303</pub-id></mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fawcett</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Vukelich</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Diaz</surname><given-names>SH</given-names></name>,
<name name-style="western"><surname>Dunklee</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Romo</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Yarns</surname><given-names>BC</given-names></name>,
<name name-style="western"><surname>Escalona</surname><given-names>R</given-names></name></person-group>
(<year>2016</year>) <article-title>Clinical experience with high-dosage pramipexole in
patients with treatment-resistant depressive episodes in unipolar and bipolar
depression</article-title>. <source>Am J
Psychiatry</source><volume>173</volume>:<fpage>107</fpage>&#x02013;<lpage>111</lpage>.<pub-id pub-id-type="pmid">26844792</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="other">
<person-group person-group-type="author"><collab>FDA</collab></person-group> (<year>2017</year>) Food and Drug Administration escitalopram prescribing
information. Available online (<ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021323s047lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021323s047lbl.pdf</ext-link>,
accessed on <comment>July 3, 2017</comment>.</mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Felger</surname><given-names>JC</given-names></name></person-group> (<year>2017</year>) <article-title>The Role of dopamine in
inflammation-associated depression: mechanisms and therapeutic
implications</article-title>. <source>Curr Top Behav
Neurosci</source><volume>31</volume>:<fpage>199</fpage>&#x02013;<lpage>219</lpage>.<pub-id pub-id-type="pmid">27225499</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Felger</surname><given-names>JC</given-names></name>,
<name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>,
<name name-style="western"><surname>Haroon</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Woolwine</surname><given-names>BJ</given-names></name>,
<name name-style="western"><surname>Jung</surname><given-names>MY</given-names></name>,
<name name-style="western"><surname>Hu</surname><given-names>X</given-names></name>,
<name name-style="western"><surname>Miller</surname><given-names>AH</given-names></name></person-group>
(<year>2016</year>) <article-title>Inflammation is associated with decreased functional
connectivity within corticostriatal reward circuitry in depression</article-title>.
<source>Mol
Psychiatry</source><volume>21</volume>:<fpage>1358</fpage>&#x02013;<lpage>1365</lpage>.<pub-id pub-id-type="pmid">26552591</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Felger</surname><given-names>JC</given-names></name>,
<name name-style="western"><surname>Treadway</surname><given-names>MT</given-names></name></person-group>
(<year>2017</year>) <article-title>Inflammation effects on motivation and motor
activity: role of dopamine</article-title>.
<source>Neuropsychopharmacology</source><volume>42</volume>:<fpage>216</fpage>&#x02013;<lpage>241</lpage>.<pub-id pub-id-type="pmid">27480574</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Haapakoski</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Mathieu</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Ebmeier</surname><given-names>KP</given-names></name>,
<name name-style="western"><surname>Alenius</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Kivimaki</surname><given-names>M</given-names></name></person-group>
(<year>2015</year>) <article-title>Cumulative meta-analysis of interleukins 6 and 1beta,
tumour necrosis factor alpha and C-reactive protein in patients with major depressive
disorder</article-title>. <source>Brain Behav
Immun</source><volume>49</volume>:<fpage>206</fpage>&#x02013;<lpage>215</lpage>.<pub-id pub-id-type="pmid">26065825</pub-id></mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hannestad</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>DellaGioia</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Bloch</surname><given-names>M</given-names></name></person-group>
(<year>2011</year>) <article-title>The effect of antidepressant medication treatment on
serum levels of inflammatory cytokines: a meta-analysis</article-title>.
<source>Neuropsychopharmacology</source><volume>36</volume>:<fpage>2452</fpage>&#x02013;<lpage>2459</lpage>.<pub-id pub-id-type="pmid">21796103</pub-id></mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Honorati</surname><given-names>MC</given-names></name>,
<name name-style="western"><surname>Neri</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Cattini</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Facchini</surname><given-names>A</given-names></name></person-group>
(<year>2006</year>) <article-title>Interleukin-17, a regulator of angiogenic factor
release by synovial fibroblasts</article-title>. <source>Osteoarthritis
Cartilage</source><volume>14</volume>:<fpage>345</fpage>&#x02013;<lpage>352</lpage>.<pub-id pub-id-type="pmid">16311048</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Huppert</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Closhen</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Croxford</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>White</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Kulig</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Pietrowski</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Bechmann</surname><given-names>I</given-names></name>,
<name name-style="western"><surname>Becher</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Luhmann</surname><given-names>HJ</given-names></name>,
<name name-style="western"><surname>Waisman</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Kuhlmann</surname><given-names>CR</given-names></name></person-group>
(<year>2010</year>) <article-title>Cellular mechanisms of IL-17-induced blood-brain
barrier disruption</article-title>. <source>FASEB
J</source><volume>24</volume>:<fpage>1023</fpage>&#x02013;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">19940258</pub-id></mixed-citation></ref><ref id="CIT0023a"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jha MK</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Gadad</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Greer</surname><given-names>TL</given-names></name>,
<name name-style="western"><surname>Mayes</surname><given-names>TL</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name></person-group> (<year>2017a</year>) <article-title>Interleukin 17 Selectively Predicts
Better Outcomes with Bupropion-SSRI Combination: Novel T Cell Biomarker for
Antidepressant Medication Selection. Brain Behav Immun. Jul 8.
pii:</article-title><fpage>S0889</fpage>-<lpage>1591(17)30212-X</lpage>. doi:
<comment>10.1016/j.bbi.2017.07.005</comment>.</mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jha</surname><given-names>MK</given-names></name>,
<name name-style="western"><surname>Minhajuddin</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Gadad</surname><given-names>BS</given-names></name>,
<name name-style="western"><surname>Greer</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Grannemann</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Soyombo</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Mayes</surname><given-names>TL</given-names></name>,
<name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name></person-group>
(<year>2017b</year>) <article-title>Can C-reactive protein inform antidepressant
medication selection in depressed outpatients? Findings from the CO-MED
trial</article-title>.
<source>Psychoneuroendocrinology</source><volume>78</volume>:<fpage>105</fpage>&#x02013;<lpage>113</lpage>.<pub-id pub-id-type="pmid">28187400</pub-id></mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kappelmann</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Lewis</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Dantzer</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Jones</surname><given-names>PB</given-names></name>,
<name name-style="western"><surname>Khandaker</surname><given-names>GM</given-names></name></person-group>
(<year>2016</year>) <article-title>Antidepressant activity of anti-cytokine treatment: a
systematic review and meta-analysis of clinical trials of chronic inflammatory
conditions</article-title>. <source>Mol Psychiatry</source> doi:
<comment>10.1038/mp.2016.167</comment> [Epub ahead of print].</mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kawanokuchi</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Shimizu</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Nitta</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Yamada</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Mizuno</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Takeuchi</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Suzumura</surname><given-names>A</given-names></name></person-group>
(<year>2008</year>) <article-title>Production and functions of IL-17 in
microglia</article-title>. <source>J Neuroimmunol</source>.
<volume>194</volume>:<fpage>54</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="pmid">18164424</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kebir</surname><given-names>H</given-names></name>,
<name name-style="western"><surname>Kreymborg</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Ifergan</surname><given-names>I</given-names></name>,
<name name-style="western"><surname>Dodelet-Devillers</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Cayrol</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Bernard</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Giuliani</surname><given-names>F</given-names></name>,
<name name-style="western"><surname>Arbour</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Becher</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Prat</surname><given-names>A</given-names></name></person-group>
(<year>2007</year>) <article-title>Human TH17 lymphocytes promote blood-brain barrier
disruption and central nervous system inflammation</article-title>. <source>Nat
Med</source><volume>13</volume>:<fpage>1173</fpage>&#x02013;<lpage>1175</lpage>.<pub-id pub-id-type="pmid">17828272</pub-id></mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>K&#x000f6;hler-Forsberg</surname><given-names>O</given-names></name>,
<name name-style="western"><surname>Buttensch&#x000f8;n</surname><given-names>HN</given-names></name>,
<name name-style="western"><surname>Tansey</surname><given-names>KE</given-names></name>,
<name name-style="western"><surname>Maier</surname><given-names>W</given-names></name>,
<name name-style="western"><surname>Hauser</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Dernovsek</surname><given-names>MZ</given-names></name>,
<name name-style="western"><surname>Henigsberg</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Souery</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Farmer</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Rietschel</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>McGuffin</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Aitchison</surname><given-names>KJ</given-names></name>,
<name name-style="western"><surname>Uher</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Mors</surname><given-names>O</given-names></name></person-group>
(<year>2017</year>) <article-title>Association between C-reactive protein (CRP) with
depression symptom severity and specific depressive symptoms in major
depression</article-title>. <source>Brain Behav
Immun</source><volume>62</volume>:<fpage>344</fpage>&#x02013;<lpage>350</lpage>.<pub-id pub-id-type="pmid">28257825</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Marin</surname><given-names>RS</given-names></name></person-group> (<year>1990</year>) <article-title>Differential diagnosis and
classification of apathy</article-title>. <source>Am J
Psychiatry</source><volume>147</volume>:<fpage>22</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">2403472</pub-id></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>AH</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Jha</surname><given-names>MK</given-names></name></person-group>
(<year>2017a</year>) <article-title>Is C-reactive protein ready for prime time in the
selection of antidepressant
medications?</article-title><source>Psychoneuroendocrinology</source> doi:
<comment>10.1016/j.psyneuen.2017.04.006</comment>. [Epub ahead of
print].</mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>AH</given-names></name>,
<name name-style="western"><surname>Haroon</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Felger</surname><given-names>JC</given-names></name></person-group>
(<year>2017b</year>) <article-title>Therapeutic implications of brain-immune
interactions: treatment in translation</article-title>.
<source>Neuropsychopharmacology</source><volume>42</volume>:<fpage>334</fpage>&#x02013;<lpage>359</lpage>.<pub-id pub-id-type="pmid">27555382</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Raison</surname><given-names>CL</given-names></name>,
<name name-style="western"><surname>Rutherford</surname><given-names>RE</given-names></name>,
<name name-style="western"><surname>Woolwine</surname><given-names>BJ</given-names></name>,
<name name-style="western"><surname>Shuo</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Schettler</surname><given-names>P</given-names></name>,
<name name-style="western"><surname>Drake</surname><given-names>DF</given-names></name>,
<name name-style="western"><surname>Haroon</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Miller</surname><given-names>AH</given-names></name></person-group>
(<year>2013</year>) <article-title>A randomized controlled trial of the tumor necrosis
factor antagonist infliximab for treatment-resistant depression: the role of baseline
inflammatory biomarkers</article-title>. <source>JAMA
Psychiatry</source><volume>70</volume>:<fpage>31</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">22945416</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Gullion</surname><given-names>CM</given-names></name>,
<name name-style="western"><surname>Basco</surname><given-names>MR</given-names></name>,
<name name-style="western"><surname>Jarrett</surname><given-names>RB</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name></person-group>
(<year>1996</year>) <article-title>The Inventory of depressive symptomatology (IDS):
psychometric properties</article-title>. <source>Psychol
Med</source><volume>26</volume>:<fpage>477</fpage>&#x02013;<lpage>486</lpage>.<pub-id pub-id-type="pmid">8733206</pub-id></mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Ibrahim</surname><given-names>HM</given-names></name>,
<name name-style="western"><surname>Carmody</surname><given-names>TJ</given-names></name>,
<name name-style="western"><surname>Arnow</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Klein</surname><given-names>DN</given-names></name>,
<name name-style="western"><surname>Markowitz</surname><given-names>JC</given-names></name>,
<name name-style="western"><surname>Ninan</surname><given-names>PT</given-names></name>,
<name name-style="western"><surname>Kornstein</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Manber</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Thase</surname><given-names>ME</given-names></name>,
<name name-style="western"><surname>Kocsis</surname><given-names>JH</given-names></name>,
<name name-style="western"><surname>Keller</surname><given-names>MB</given-names></name></person-group>
(<year>2003</year>) <article-title>The 16-Item Quick Inventory of Depressive
Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a
psychometric evaluation in patients with chronic major depression</article-title>.
<source>Biol
Psychiatry</source><volume>54</volume>:<fpage>573</fpage>&#x02013;<lpage>583</lpage>.<pub-id pub-id-type="pmid">12946886</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Bernstein</surname><given-names>IH</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Carmody</surname><given-names>TJ</given-names></name>,
<name name-style="western"><surname>Wisniewski</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Mundt</surname><given-names>JC</given-names></name>,
<name name-style="western"><surname>Shores-Wilson</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Biggs</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Woo</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></name>,
<name name-style="western"><surname>Fava</surname><given-names>M</given-names></name></person-group>
(<year>2006a</year>) <article-title>An evaluation of the Quick Inventory of Depressive
Symptomatology and the Hamilton Rating Scale for Depression: a sequenced treatment
alternatives to relieve depression trial report</article-title>. <source>Biol
Psychiatry</source><volume>59</volume>:<fpage>493</fpage>&#x02013;<lpage>501</lpage>.<pub-id pub-id-type="pmid">16199008</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Wisniewski</surname><given-names>SR</given-names></name>,
<name name-style="western"><surname>Stewart</surname><given-names>JW</given-names></name>,
<name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></name>,
<name name-style="western"><surname>Thase</surname><given-names>ME</given-names></name>,
<name name-style="western"><surname>Ritz</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Biggs</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Warden</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Luther</surname><given-names>JF</given-names></name>,
<name name-style="western"><surname>Shores-Wilson</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Niederehe</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Fava</surname><given-names>M</given-names></name></person-group>
(<year>2006b</year>) <article-title>Bupropion-SR, sertraline, or venlafaxine-XR after
failure of SSRIs for depression</article-title>. <source>N Engl J
Med</source><volume>354</volume>:<fpage>1231</fpage>&#x02013;<lpage>1242</lpage>.<pub-id pub-id-type="pmid">16554525</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Wisniewski</surname><given-names>SR</given-names></name>,
<name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></name>,
<name name-style="western"><surname>Stewart</surname><given-names>JW</given-names></name>,
<name name-style="western"><surname>Warden</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Niederehe</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Thase</surname><given-names>ME</given-names></name>,
<name name-style="western"><surname>Lavori</surname><given-names>PW</given-names></name>,
<name name-style="western"><surname>Lebowitz</surname><given-names>BD</given-names></name>,
<name name-style="western"><surname>McGrath</surname><given-names>PJ</given-names></name>,
<name name-style="western"><surname>Rosenbaum</surname><given-names>JF</given-names></name>,
<name name-style="western"><surname>Sackeim</surname><given-names>HA</given-names></name>,
<name name-style="western"><surname>Kupfer</surname><given-names>DJ</given-names></name>,
<name name-style="western"><surname>Luther</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Fava</surname><given-names>M</given-names></name></person-group>
(<year>2006c</year>) <article-title>Acute and longer-term outcomes in depressed
outpatients requiring one or several treatment steps: a STAR*D report</article-title>.
<source>Am J
Psychiatry</source><volume>163</volume>:<fpage>1905</fpage>&#x02013;<lpage>1917</lpage>.<pub-id pub-id-type="pmid">17074942</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Stewart</surname><given-names>JW</given-names></name>,
<name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></name>,
<name name-style="western"><surname>Fava</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Kurian</surname><given-names>BT</given-names></name>,
<name name-style="western"><surname>Warden</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Morris</surname><given-names>DW</given-names></name>,
<name name-style="western"><surname>Luther</surname><given-names>JF</given-names></name>,
<name name-style="western"><surname>Husain</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Cook</surname><given-names>IA</given-names></name>,
<name name-style="western"><surname>Shelton</surname><given-names>RC</given-names></name>,
<name name-style="western"><surname>Lesser</surname><given-names>IM</given-names></name>,
<name name-style="western"><surname>Kornstein</surname><given-names>SG</given-names></name>,
<name name-style="western"><surname>Wisniewski</surname><given-names>SR</given-names></name></person-group>
(<year>2011</year>) <article-title>Combining medications to enhance depression outcomes
(CO-MED): acute and long-term outcomes of a single-blind randomized
study</article-title>. <source>Am J
Psychiatry</source><volume>168</volume>:<fpage>689</fpage>&#x02013;<lpage>701</lpage>.<pub-id pub-id-type="pmid">21536692</pub-id></mixed-citation></ref><ref id="CIT0038"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sarma</surname><given-names>JD</given-names></name>,
<name name-style="western"><surname>Ciric</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Marek</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Sadhukhan</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Caruso</surname><given-names>ML</given-names></name>,
<name name-style="western"><surname>Shafagh</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Fitzgerald</surname><given-names>DC</given-names></name>,
<name name-style="western"><surname>Shindler</surname><given-names>KS</given-names></name>,
<name name-style="western"><surname>Rostami</surname><given-names>A</given-names></name></person-group>
(<year>2009</year>) <article-title>Functional interleukin-17 receptor A is expressed in
central nervous system glia and upregulated in experimental autoimmune
encephalomyelitis</article-title>. <source>J
Neuroimmunol</source><volume>6</volume>:<fpage>14</fpage>.</mixed-citation></ref><ref id="CIT0039"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schatzberg</surname><given-names>AF</given-names></name>,
<name name-style="western"><surname>DeBattista</surname><given-names>C</given-names></name>,
<name name-style="western"><surname>Lazzeroni</surname><given-names>LC</given-names></name>,
<name name-style="western"><surname>Etkin</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Greer</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Murphy</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Williams</surname><given-names>LM</given-names></name></person-group>
(<year>2015</year>) <article-title>ABCB1 genetic effects on antidepressant outcomes: a
report from the iSPOT-D Trial</article-title>. <source>Am J
Psychiatry</source><volume>172</volume>:<fpage>751</fpage>&#x02013;<lpage>759</lpage>.<pub-id pub-id-type="pmid">25815420</pub-id></mixed-citation></ref><ref id="CIT0040"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Shelton</surname><given-names>RC</given-names></name>,
<name name-style="western"><surname>Falola</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Li</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Zajecka</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Fava</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Papakostas</surname><given-names>GI</given-names></name></person-group>
(<year>2015</year>) <article-title>The pro-inflammatory profile of depressed patients is
(partly) related to obesity</article-title>. <source>J Psychiatr
Res</source><volume>70</volume>:<fpage>91</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">26424427</pub-id></mixed-citation></ref><ref id="CIT0041"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Snaith</surname><given-names>RP</given-names></name>,
<name name-style="western"><surname>Hamilton</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Morley</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Humayan</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Hargreaves</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Trigwell</surname><given-names>P</given-names></name></person-group>
(<year>1995</year>) <article-title>A scale for the assessment of hedonic tone the
Snaith-Hamilton Pleasure Scale</article-title>. <source>Br J
Psychiatry</source><volume>167</volume>:<fpage>99</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="pmid">7551619</pub-id></mixed-citation></ref><ref id="CIT0042"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Swardfager</surname><given-names>W</given-names></name>,
<name name-style="western"><surname>Rosenblat</surname><given-names>JD</given-names></name>,
<name name-style="western"><surname>Benlamri</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>McIntyre</surname><given-names>RS</given-names></name></person-group>
(<year>2016</year>) <article-title>Mapping inflammation onto mood: inflammatory
mediators of anhedonia</article-title>. <source>Neurosci Biobehav
Rev</source><volume>64</volume>:<fpage>148</fpage>&#x02013;<lpage>166</lpage>.<pub-id pub-id-type="pmid">26915929</pub-id></mixed-citation></ref><ref id="CIT0043"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Toups</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name></person-group>
(<year>2012</year>) <article-title>Biomarkers and the future of treatment for
depression</article-title>.
<source>Cerebrum</source><volume>2012</volume>:<fpage>6</fpage>.<pub-id pub-id-type="pmid">23447792</pub-id></mixed-citation></ref><ref id="CIT0044"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name></person-group> (<year>2013</year>) <article-title>Modeling predictors, moderators and
mediators of treatment outcome and resistance in depression</article-title>.
<source>Biol
Psychiatry</source><volume>74</volume>:<fpage>2</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">23787333</pub-id></mixed-citation></ref><ref id="CIT0045"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name></person-group> (<year>2016</year>) <article-title>Right patient, right treatment, right
time: biosignatures and precision medicine in depression</article-title>. <source>World
Psychiatry</source><volume>15</volume>:<fpage>237</fpage>&#x02013;<lpage>238</lpage>.<pub-id pub-id-type="pmid">27717250</pub-id></mixed-citation></ref><ref id="CIT0046"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Ibrahim</surname><given-names>HM</given-names></name>,
<name name-style="western"><surname>Carmody</surname><given-names>TJ</given-names></name>,
<name name-style="western"><surname>Biggs</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Suppes</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Crismon</surname><given-names>ML</given-names></name>,
<name name-style="western"><surname>Shores-Wilson</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Toprac</surname><given-names>MG</given-names></name>,
<name name-style="western"><surname>Dennehy</surname><given-names>EB</given-names></name>,
<name name-style="western"><surname>Witte</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>Kashner</surname><given-names>TM</given-names></name></person-group>
(<year>2004</year>) <article-title>The Inventory of Depressive Symptomatology, Clinician
Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive
Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector
patients with mood disorders: a psychometric evaluation</article-title>. <source>Psychol
Med</source><volume>34</volume>:<fpage>73</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">14971628</pub-id></mixed-citation></ref><ref id="CIT0047"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Fava</surname><given-names>M</given-names></name>,
<name name-style="western"><surname>Wisniewski</surname><given-names>SR</given-names></name>,
<name name-style="western"><surname>Thase</surname><given-names>ME</given-names></name>,
<name name-style="western"><surname>Quitkin</surname><given-names>F</given-names></name>,
<name name-style="western"><surname>Warden</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Ritz</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></name>,
<name name-style="western"><surname>Lebowitz</surname><given-names>BD</given-names></name>,
<name name-style="western"><surname>Biggs</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Luther</surname><given-names>JF</given-names></name>,
<name name-style="western"><surname>Shores-Wilson</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name></person-group>
(<year>2006a</year>) <article-title>Medication augmentation after the failure of SSRIs
for depression</article-title>. <source>N Engl J Med</source>.
<volume>354</volume>:<fpage>1243</fpage>&#x02013;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">16554526</pub-id></mixed-citation></ref><ref id="CIT0048"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Wisniewski</surname><given-names>SR</given-names></name>,
<name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></name>,
<name name-style="western"><surname>Warden</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Ritz</surname><given-names>L</given-names></name>,
<name name-style="western"><surname>Norquist</surname><given-names>G</given-names></name>,
<name name-style="western"><surname>Howland</surname><given-names>RH</given-names></name>,
<name name-style="western"><surname>Lebowitz</surname><given-names>B</given-names></name>,
<name name-style="western"><surname>McGrath</surname><given-names>PJ</given-names></name>,
<name name-style="western"><surname>Shores-Wilson</surname><given-names>K</given-names></name>,
<name name-style="western"><surname>Biggs</surname><given-names>MM</given-names></name>,
<name name-style="western"><surname>Balasubramani</surname><given-names>GK</given-names></name>,
<name name-style="western"><surname>Fava</surname><given-names>M</given-names></name></person-group>
(<year>2006b</year>) <article-title>Evaluation of outcomes with citalopram for
depression using measurement-based care in STAR*D: implications for clinical
practice</article-title>. <source>Am J
Psychiatry</source><volume>163</volume>:<fpage>28</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">16390886</pub-id></mixed-citation></ref><ref id="CIT0049"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name><etal/></person-group> (<year>2016</year>) <article-title>Establishing moderators and
biosignatures of antidepressant response in clinical care (EMBARC): Rationale and
design</article-title>. <source>J Psychiatr
Res</source><volume>78</volume>:<fpage>11</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">27038550</pub-id></mixed-citation></ref><ref id="CIT0050"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Uher</surname><given-names>R</given-names></name>,
<name name-style="western"><surname>Tansey</surname><given-names>KE</given-names></name>,
<name name-style="western"><surname>Dew</surname><given-names>T</given-names></name>,
<name name-style="western"><surname>Maier</surname><given-names>W</given-names></name>,
<name name-style="western"><surname>Mors</surname><given-names>O</given-names></name>,
<name name-style="western"><surname>Hauser</surname><given-names>J</given-names></name>,
<name name-style="western"><surname>Dernovsek</surname><given-names>MZ</given-names></name>,
<name name-style="western"><surname>Henigsberg</surname><given-names>N</given-names></name>,
<name name-style="western"><surname>Souery</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Farmer</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>McGuffin</surname><given-names>P</given-names></name></person-group>
(<year>2014</year>) <article-title>An inflammatory biomarker as a differential predictor
of outcome of depression treatment with escitalopram and nortriptyline</article-title>.
<source>Am J
Psychiatry</source><volume>171</volume>:<fpage>1278</fpage>&#x02013;<lpage>1286</lpage>.<pub-id pub-id-type="pmid">25017001</pub-id></mixed-citation></ref><ref id="CIT0051"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vichaya</surname><given-names>EG</given-names></name>,
<name name-style="western"><surname>Hunt</surname><given-names>SC</given-names></name>,
<name name-style="western"><surname>Dantzer</surname><given-names>R</given-names></name></person-group>
(<year>2014</year>) <article-title>Lipopolysaccharide reduces incentive motivation while
boosting preference for high reward in mice</article-title>.
<source>Neuropsychopharmacology</source><volume>39</volume>:<fpage>
2884</fpage>&#x02013;<lpage>2890</lpage>.<pub-id pub-id-type="pmid">24917202</pub-id></mixed-citation></ref><ref id="CIT0052"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>ML</given-names></name>,
<name name-style="western"><surname>Frank</surname><given-names>E</given-names></name>,
<name name-style="western"><surname>Kraemer</surname><given-names>HC</given-names></name></person-group>
(<year>2013</year>) <article-title>A novel approach for developing and interpreting
treatment moderator profiles in randomized clinical trials</article-title>. <source>JAMA
Psychiatry</source><volume>70</volume>:<fpage>1241</fpage>&#x02013;<lpage>1247</lpage>.<pub-id pub-id-type="pmid">24048258</pub-id></mixed-citation></ref><ref id="CIT0053"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wallace</surname><given-names>ML</given-names></name>,
<name name-style="western"><surname>McMakin</surname><given-names>DL</given-names></name>,
<name name-style="western"><surname>Tan</surname><given-names>PZ</given-names></name>,
<name name-style="western"><surname>Rosen</surname><given-names>D</given-names></name>,
<name name-style="western"><surname>Forbes</surname><given-names>EE</given-names></name>,
<name name-style="western"><surname>Ladouceur</surname><given-names>CD</given-names></name>,
<name name-style="western"><surname>Ryan</surname><given-names>ND</given-names></name>,
<name name-style="western"><surname>Siegle</surname><given-names>GJ</given-names></name>,
<name name-style="western"><surname>Dahl</surname><given-names>RE</given-names></name>,
<name name-style="western"><surname>Kendall</surname><given-names>PC</given-names></name>,
<name name-style="western"><surname>Mannarino</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Silk</surname><given-names>JS</given-names></name></person-group>
(<year>2017</year>) <article-title>The role of day-to-day emotions, sleep, and social
interactions in pediatric anxiety treatment</article-title>. <source>Behav Res
Ther</source><volume>90</volume>:<fpage>87</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">28013054</pub-id></mixed-citation></ref><ref id="CIT0054"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Warner-Schmidt</surname><given-names>JL</given-names></name>,
<name name-style="western"><surname>Vanover</surname><given-names>KE</given-names></name>,
<name name-style="western"><surname>Chen</surname><given-names>EY</given-names></name>,
<name name-style="western"><surname>Marshall</surname><given-names>JJ</given-names></name>,
<name name-style="western"><surname>Greengard</surname><given-names>P</given-names></name></person-group>
(<year>2011</year>) <article-title>Antidepressant effects of selective serotonin
reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and
humans</article-title>. <source>Proc Natl Acad Sci U S
A</source><volume>108</volume>:<fpage>9262</fpage>&#x02013;<lpage>9267</lpage>.<pub-id pub-id-type="pmid">21518864</pub-id></mixed-citation></ref><ref id="CIT0055"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wisniewski</surname><given-names>SR</given-names></name>,
<name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name>,
<name name-style="western"><surname>Balasubramani</surname><given-names>GK</given-names></name>,
<name name-style="western"><surname>Trivedi</surname><given-names>MH</given-names></name>,
<name name-style="western"><surname>Nierenberg</surname><given-names>AA</given-names></name></person-group>
(<year>2006</year>) <article-title>Self-rated global measure of the frequency,
intensity, and burden of side effects</article-title>. <source>J Psychiatr
Pract</source><volume> 12</volume>:<fpage>71</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">16728903</pub-id></mixed-citation></ref><ref id="CIT0056"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wohleb</surname><given-names>ES</given-names></name>,
<name name-style="western"><surname>McKim</surname><given-names>DB</given-names></name>,
<name name-style="western"><surname>Sheridan</surname><given-names>JF</given-names></name>,
<name name-style="western"><surname>Godbout</surname><given-names>JP</given-names></name></person-group>
(<year>2014</year>) <article-title>Monocyte trafficking to the brain with stress and
inflammation: a novel axis of immune-to-brain communication that influences mood and
behavior</article-title>. <source>Front
Neurosci</source><volume>8</volume>:<fpage>447</fpage>.<pub-id pub-id-type="pmid">25653581</pub-id></mixed-citation></ref></ref-list></back></article>